Cargando…
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement
PURPOSE: Patients suffering from aggressive systemic peripheral lymphoma with primary central nervous system involvement (PCL) are a rare and sparsely investigated population. Recommended treatment regimens include a combination of intrathecal and systemic chemotherapy as well as whole brain radioth...
Autores principales: | Steinhardt, Maximilian J., Krummenast, Franziska C., Rosenwald, Andreas, Gerhard-Hartmann, Elena, Heidemeier, Anke, Einsele, Hermann, Topp, Max S., Duell, Johannes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752544/ https://www.ncbi.nlm.nih.gov/pubmed/34085097 http://dx.doi.org/10.1007/s00432-021-03663-x |
Ejemplares similares
-
DNA tape measurements of AraC
por: Rodgers, Michael E., et al.
Publicado: (2008) -
aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021) -
AraC-Based Biosensor
for the Detection of Isoprene
in E. coli
por: Bhat, Shrilaxmi, et al.
Publicado: (2023) -
Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.
por: Richardson, V. J., et al.
Publicado: (1982) -
Reduced prefrontal cortex and sympathetic nervous system activity correlate with fatigue after aHSCT
por: Boberg, Erik, et al.
Publicado: (2021)